Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2024-04-12FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation. The approval leads to chang…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients [Phase 4]
Phase 4 trial evaluating the immunogenicity of the recombinant zoster vaccine in patients with multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: Time Restricted Eating Outcomes in Multiple Sclerosis [NA]
Completed clinical trial evaluating time-restricted eating effects in individuals with multiple sclerosis; results posted in 2024.
-
FDA approval · 2024-03-22FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
FDA approval · 2024-03-19FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA (glatiramer acetate) from Sandoz Inc, updating regulatory status for this product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-03-19FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA (glatiramer acetate) submitted by Sandoz Inc.
-
FDA approval · 2024-03-12FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
The U.S. FDA has approved Biogen's supplemental application for Tecfidera (dimethyl fumarate) related to its use in multiple sclerosis, refl…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab [Phase 3]
A Phase 3 trial comparing pretreatment with cetirizine versus diphenhydramine to assess risk and severity of infusion reactions in patients …
-
FDA approval · 2024-02-28FDA Approved: FINGOLIMOD — Original Application (Aurobindo Pharma Limited)
FDA approved a generic fingolimod product from Aurobindo Pharma Limited (ANDA 207983) under Original Application. Fingolimod is used to trea…
-
FDA approval · 2024-02-15FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for glatiramer acetate by Mylan Pharmaceuticals, authorizing a generic version of the therapy for mu…
-
FDA approval · 2024-02-15FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for glatiramer acetate from Mylan Pharmaceuticals, indicating a regulatory change to this produc…
-
FDA approval · 2024-02-08FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith Laboratories' supplemental application for a generic dimethyl fumarate product. The approval enables the generic t…
-
FDA approval · 2024-02-08FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for dimethyl fumarate (ANDA 210305) by Cipla USA Inc., enabling the continued market availability of…
-
FDA label_change · 2024-02-08FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for Dimethyl Fumarate from Glenmark Pharmaceuticals Inc., USA, typically resulting in label or packa…
-
FDA approval · 2024-02-07FDA Approved: MAVENCLAD — Supplemental Application (EMD Serono, Inc.)
The FDA approved a supplemental application for Mavenclad (cladribine) submitted by EMD Serono, Inc., updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety and tolerability of ISX (Isoxsuprine HCL) in multiple sclerosis relapses has completed with…
-
FDA approval · 2024-02-05FDA Approved: BACLOFEN — Supplemental Application (TruPharma LLC)
FDA approved TruPharma LLC's supplemental application for baclofen (generic) under the approved regulatory pathway.
-
CLINICAL_TRIALS research · 2024-02-05Clinical Trial Update: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Clinical trial update investigating meningeal inflammation on 7T MRI as a biomarker to measure and predict ocrelizumab response in multiple …
-
CLINICAL_TRIALS trial_result · 2024-02-05Clinical Trial Update: Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis [Phase 3]
A Phase 3 trial evaluating Nabiximols Oromucosal Spray for spasticity in people with multiple sclerosis was terminated; results have been po…
-
CLINICAL_TRIALS trial_result · 2024-01-31Clinical Trial Update: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis [Phase 3]
Phase 3 clinical trial evaluating AP707 for chronic pain due to central neuropathy; efficacy and tolerability data are not yet fully disclos…
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis [Phase 3]
Open-label Phase 3 extension trial of oral RPC1063 in relapsing multiple sclerosis completed; results posted.
-
CLINICAL_TRIALS withdrawal · 2024-01-23Clinical Trial Update: A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial evaluating ocrelizumab for leptomeningeal inflammation in multiple sclerosis has been withdrawn.
-
FDA approval · 2024-01-19FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Kesimpta (ofatumumab) submitted by Novartis Pharmaceuticals Corporation. This action updates the…
-
FDA approval · 2024-01-19FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for OCREVUS (ocrelizumab) by Genentech, Inc., expanding the approved use for multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI [NA]
Clinical trial updates on tDCS-induced neuronal responses in multiple sclerosis using advanced MRI; study completed with posted results.